SFDA Takes Legal Action Against Expatriate for Selling Unregistered Medicines
The Saudi Food and Drug Authority (SFDA) has taken action against an expat in Dammam for selling unlicensed pharmaceutical products, emphasizing the seriousness of such violations to public health.
Dammam — The Saudi Food and Drug Authority (SFDA) has moved against an expatriate residing in Dammam by forwarding his case to the Public Prosecution.
This action follows the individual's involvement in selling unregistered pharmaceutical products, a clear contravention of the Kingdom's regulatory framework governing the licensing, production, distribution, and sale of such goods.
According to Saudi law, specifically Article 34, Paragraph 2, those found guilty of selling or possessing pharmaceuticals for trade that are adulterated, spoiled, expired, or unregistered may face penalties including imprisonment up to 10 years and/or a fine up to SR10 million.
This legislation aims to maintain the safety and efficacy of medications available within Saudi markets.
The SFDA underscored its commitment to ensuring compliance with health standards, noting that such violations are detrimental to public health and safety.
It highlighted that community cooperation in reporting observed infractions through their unified reporting number 19999 is vital for effective oversight.
The authority reiterated its firm stance against any practices endangering the quality and safety of products within Saudi markets.
This action follows the individual's involvement in selling unregistered pharmaceutical products, a clear contravention of the Kingdom's regulatory framework governing the licensing, production, distribution, and sale of such goods.
According to Saudi law, specifically Article 34, Paragraph 2, those found guilty of selling or possessing pharmaceuticals for trade that are adulterated, spoiled, expired, or unregistered may face penalties including imprisonment up to 10 years and/or a fine up to SR10 million.
This legislation aims to maintain the safety and efficacy of medications available within Saudi markets.
The SFDA underscored its commitment to ensuring compliance with health standards, noting that such violations are detrimental to public health and safety.
It highlighted that community cooperation in reporting observed infractions through their unified reporting number 19999 is vital for effective oversight.
The authority reiterated its firm stance against any practices endangering the quality and safety of products within Saudi markets.
